Fabio Andrés Sinisterra Solís, Médico Nuclear adscrito al Departamento de Medicina Nuclear – Oncología Nuclear del Instituto Nacional de Cancerología de México y a la Unidad de Imagen Molecular PET/CT de Salud Digna, Ciudad de México, México. Estudié medicina general en la Fundación Universitaria San Martín, Cali - Colombia, y trabajé en Colombia como médico general durante 7 años en diversos campos como neurología y medicina interna. Posteriormente, estudié medicina nuclear en la Universidad Nacional Autónoma de México (UNAM) – Centro Médico Nacional Siglo XXI; también realicé cursos de posgrado en Oncología Nuclear (Instituto Nacional de Cancerología de México) y Neurociencias Nucleares (Instituto Nacional de Cancerología de México), ambos acreditados por la UNAM. Llevo aproximadamente dos años trabajando como médico nuclear, especializándome en técnicas como PET/CT y SPECT/CT con múltiples trazadores en aplicaciones oncológicas y neurológicas. También he participado en varias publicaciones en estos campos y actualmente soy miembro activo de la Society of Nuclear Medicine and Molecular Imaging.
Francisco Rubén Romero Castellanos, Chief of the Molecular Imaging
Service at Christus Muguerza, Betania Hospital in Puebla. I obtained my
Bachelor of Medicine and Surgery from Cristóbal Colón University (2011–2017),
followed by a specialty in Nuclear Medicine and Molecular Imaging at the
National Autonomous University of Mexico (UNAM) from 2019 to 2022. I also
completed a high specialty in nuclear neurosciences at UNAM from 2022 to 2023.
I served as head of the Nuclear Medicine and Molecular Imaging Service at
Centenario Hospital Miguel Hidalgo and Mac Norte Hospital in Aguascalientes
from 2022 to 2024 and was President of the Biosafety Committee at Centenario
Hospital Miguel Hidalgo in 2023–2024. My research focuses on
neurodegenerative diseases, including various forms of dementia, movement
disorders, and encephalitis. My recent publications include studies on 18F-FDG
PET/CT in ALS, Bickerstaff encephalitis, and progressive primary aphasia, which were
featured in prominent journals like Frontiers in Nuclear Medicine and Clinical
and Translational Imaging.
Emilly Alejandra Cortés Mancera, Nuclear medicine physician at the Nuclear Medicine and Molecular Imaging Service of the Central South High Specialty Hospital of Petróleos Mexicanos. I earned my medical degree from the National Autonomous University of Mexico (UNAM) from 2012 to 2018. I specialized in nuclear medicine at the Hospital de Especialidades, Centro Médico Nacional Siglo XXI, from 2018 to 2021 and completed a fellowship in PET-CT at Hospital Ángeles Pedregal from 2021 to 2022. I have worked in the PET-CT Department at Hospital Ángeles Pedregal and in Nuclear Medicine at the Central South Hospital. Currently, I lead the Nuclear Medicine and Molecular Imaging Service at the Central South Hospital. I am a member of the European Association of Nuclear Medicine and the Radiological Society of North America. My research includes the study of a new radioligand for insulinomas, presented at the EANM 21 congress, and an article on effective communication of bad news in medicine, published in Rev Investigación en Discapacidad. I received first place for my work on SPECT/CT in diagnosing insulinomas at the VIII National Congress of the Mexican Federation of Nuclear Medicine in 2019.
M.Sc. Ana Lucía Calderón Avila is a Nuclear Medicine and Molecular
Imaging resident at the Specialty Hospital, Centro Médico Nacional (CMN SXXI).
She graduated as a Medical Surgeon in 2018 from the Faculty of Medicine, UNAM,
and completed her Master’s in Medical Sciences with Honors at Universidad
Anáhuac, Norte, in 2023. She served as Associate Professor in the Diploma
for Health Area Educators, focusing on research methodology and biostatistics,
from 2019 to 2021 at the Division of Graduate Studies, Faculty of Medicine,
UNAM. She was a research assistant to an Emeritus SNI III researcher at the
National Institute of Genomic Medicine (INMEGEN) from 2018 to 2019. Her
research lines includes the following: Evaluation of myocardial function in patients with
secondary HPT using 99mTc-MIBI SPECT/CT and oxidative stress markers,
2024–present, at Specialty Hospital, CMN SXXI; Evaluation of the molecular
phenotype of breast cancer and bone metastasis patterns using 99mTc-MDP bone
scans, 2023–present, at Specialty Hospital, CMN SXXI; Transcriptome analysis
via NGS in patients with osteosarcoma, 2020–2022, at the National
Rehabilitation Institute; Clinical and genomic characterization of Marfan
syndrome, case series study, 2017–2019, at INMEGEN; and Clinical and molecular
characterization of hypertrophic and dilated cardiomyopathy, either familial or
idiopathic, 2017–2019, at INMEGEN.
Sofía Denisse González Rueda studied medicine at Universidad
Autonoma de Chiapas, prepared to be a nuclear medicine physician specialist, and
graduated from Mexico’s National Cancer Institute – Universidad Nacional Autonoma
de México (INCan – UNAM). Sofie is currently working on a nuclear oncology fellowship also
at INCan – UNAM. Sofia has experience is in the theragnosis field in a specialized center with
oncologic and non-oncologic patients with techniques used in conventional
nuclear medicine, as well as hybrid imaging like SPECT/CT and PET/CT, over and
above administering targeted therapies with alpha and betta radionuclide
emitters. Sofia has been a speaker at local and national congresses and a scientific researcher,
author, and collaborator of national and international abstracts and papers in
topics such as pathologic conditions in pregnancy (like gestational diabetes
and gestational hypertension), cardiac and neurologic diseases, thyroid cancer,
prostate cancer, lung cancer, and testicular cancer, among others.
Juan Salvador Rosales García, currently assigned to the PET/CT Molecular
Imaging area at the National Institute of Neurology and Neurosurgery, was born
on April 2, 1990, in Villa de Las Flores, State of Mexico. He earned his
medical degree from the Higher School of Medicine, National Polytechnic
Institute (IPN) in Mexico, from 2012 to 2018. He then completed a specialty in
Nuclear Medicine and Molecular Imaging at the National Institute of Respiratory
Diseases (INER), endorsed by the National Autonomous University of Mexico
(UNAM), in 2020. Following this, he undertook a fellowship in Nuclear
Neurosciences at the National Institute of Neurology and Neurosurgery, which he
finished in 2023. Since 2024, he has been working in the PET/CT Molecular
Imaging area at the National Institute of Neurology and Neurosurgery. He is
also an active member of relevant professional societies.
Nora Estela Kerik Rotenberg is the head of the Molecular Imaging Department PET-CT at the National Neurological and Neurosurgery Institute since March 2011. She earned her medical degree from the Faculty of Medicine, University “La Salle,” Mexico City, between 1977 and 1981. She completed her Nuclear Medicine Fellowship at McGill University, Montreal, Canada, from 1982 to 1984, followed by PET training at UCLA, Los Angeles, California, USA, in 1999 and Cyclotron Operation and Training at Regional Nuclear Pharmaceuticals, Birmingham, Alabama, in 2001. She served as the head of the PET-Cyclotron Unit at UNAM's Faculty of Medicine from March 2000 to March 2003 and has provided consultancy for the design, installation, and operation of PET-Cyclotron Units at UNAM and in Monterrey, Nuevo León, between 1999 and 2006. She has been a Full Professor of the High Specialty in Nuclear Neuroscience at UNAM's National Neurological and Neurosurgical Institute since 2012. Her professional memberships include being a titular member of the Sociedad Mexicana de Medicina Nuclear since 1985, a graduate associate of the Nuclear Medicine Mexican Board since 1985, a titular member of the Institute for Clinical PET in the USA since 2000, a member of the International Atomic Energy Agency since 2001, and a member of the International Society for Cerebral Blood Flow and Metabolism since 2022.
